Exploring the contribution of COVID-19 prevention network to SARS-CoV-2 vaccine efficacy clinical trials COVID19 SARSCoV2 VaccineEfficacy ClinicalTrials JAMANetworkOpen thisisUIC
By Pooja Toshniwal PahariaJan 25 2023Reviewed by Aimee Molineux In a recent special communication report published in JAMA Network Open, researchers described the coronavirus disease 2019 prevention network and its contribution to clinical efficacy evaluations of COVID-19 vaccines in phase 3 trials.
About the special communication In the present study, researchers described CoVPN in assisting the coordinated execution of phase 3 clinical vaccine efficacy trials in developing COVID-19 vaccines. As a result of CoVPN’s efforts, the five clinical phase 3 trial sites included 16 nations across the Sub-Saharan regions of Africa, the United States, and South America, spanning over five continents. Additionally, in the US, sites of several NIAID-funded networks were included, such as the Native Nations, Veterans Affairs, and Defense department sites.
The SAP formulated by CoVPN statisticians collaborated with the coronavirus disease 2019 response team statistics to provide master-trial protocols for harmonized analyses and guided non-CoVPN trials. Moreover, the CoVPN statisticians had access to the findings of all five clinical trials, which provided an opportunity to answer questions that could not be answered by any of the individual studies.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Review on lateral flow test use spearheaded by SARS-CoV-2 pandemicResearchers assessed the changing landscape of lateral flow tests (LFTs), and the development of next-generation LFTs based on lessons learnt from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic.
Read more »
Mosaic RBD nanoparticles offer 100% protection against SARS-CoV-2 in animal modelA recent PNAS journal study has sought to address the above-stated drawback and developed a new strategy that involves a self-assembling scaffold of proliferating cell nuclear antigen (PCNA). This technique can develop nanoparticles containing evenly incorporated heterotypic antigens.
Read more »
Researchers identify potent pan-sarbecovirus antibodies from non-human primates vaccinated with an AS03 adjuvanted subunit SARS-CoV-2 vaccineResearchers identify potent pan-sarbecovirus antibodies from non-human primates vaccinated with an AS03 adjuvanted subunit SARS-CoV-2 vaccine biorxivpreprint Stanford scrippsresearch UNC ULLafayette vaccine vaccinated SARSCoV2
Read more »
Wastewater-based epidemiology for COVID-19 monitoring and public health protection at three UK airportsWastewater-based epidemiology for COVID-19 monitoring and public health protection at three UK airports PLOSGPH BangorUni StudentsNCL MurdochUni wastewater epidemiology COVID19 publichealth covid coronavirus
Read more »
Maternal and perinatal outcomes of women infected with SARS-CoV-2 during the Omicron wave in ItalyMaternal and perinatal outcomes of women infected with SARS-CoV-2 during the Omicron wave in Italy CMIJournal unitorvergata maternal maternalhealth pregnancy SARSCoV2 covid coronavirus covid Omicron
Read more »
Netflix producing documentary exploring Jill Dando’s unsolved murderThe BBC presenter was murdered more than 20 years ago and the killer has never been found
Read more »